| Literature DB >> 31788539 |
Joseph Marsano1, Sheeva Johnson2, Stephanie Yan2, Latifat Alli-Akintade1, Machelle Wilson3, Amar Al-Juburi1, Jesse Stondell1, Sooraj Tejaswi1.
Abstract
Objectives and study aim Colonoscopy prevents colorectal cancer by removing adenomatous polyps, but missed adenomas lead to interval cancers. Different devices have been used to increase adenoma detection rates (ADR). Two such devices of interest are the transparent cap (Olympus) and Endocuff (ARC Medical). Our study aimed to compare differences in ADR between Endocuff-assisted colonoscopy (EAC), cap-assisted colonoscopy (CAC) and standard colonoscopy (SC). Patients and methods A sample size of 126 subjects was calculated to determine an effect size of 30 %. Patients undergoing screening or surveillance colonoscopy between March 2016 and January 2017 were randomized to SC, CAC or EAC groups. Three experienced endoscopists performed all colonoscopies. Patient demographics, procedure indication, Boston Bowel Prep Score (BBPS), withdrawal time, polyp size, location, histopathology, were analyzed. Results There was no difference in ADR (52 %, 40 % and 54 %) in the SC, CAC and EAC groups respectively ( P = 0.4). Similar findings were also observed for proximal ADR (45 %, 35 %, and 50 %, P = 0.4) and SSA detection rate (16 %, 14 %, and 23 %, P = 0.5). EAC detected higher mean ADR per colonoscopy compared to CAC (1.70 vs 0.76, P = 0.01). However, there was no significant difference in mean ADR per positive colonoscopy (2.08, 1.63, and 2.59, P = 0.21). Conclusion In a randomized controlled trial comparing AC to CAC and SC, neither device conferred additional benefits in ADR among high detectors. When comparing each device, EAC may be better than CAC at detecting more total adenomas.Entities:
Year: 2019 PMID: 31788539 PMCID: PMC6877415 DOI: 10.1055/a-0996-7891
Source DB: PubMed Journal: Endosc Int Open ISSN: 2196-9736
Fig. 1Transparent cap fixed to the end of a colonoscope.
Fig. 2Endocuff with two rows of soft projections fixed to the end of a colonoscope.
Fig. 3Consolidated Standards of Reporting Trials (CONSORT) randomization flowchart. Of the eligible patients, only 235 could be contacted by phone or medical record. All randomized patients completed the study and were analyzed.
Patient demographics and baseline characteristics.
| SC n = 42 | CAC n = 42 | EAC n = 42 |
| |
| Gender | 0.97 | |||
Men, n (%) | 23 (54.8) | 24 (57.1) | 23 (54.8) | |
Women, n (%) | 19 (45.2) | 18 (42.9) | 19 (45.2) | |
| Age, mean ± sd | 59.3 ± 7.4 | 60.0 ± 6.7 | 60.0 ± 6.8 | 0.87 |
| BMI, mean ± sd | 28.5 ± 4.3 | 28.3 ± 5.5 | 27.4 ± 5.4 | 0.54 |
| Smoking Status, n (%) | 0.71 | |||
Never smoker | 30 (71.5) | 24 (57.1) | 28 (66.7) | |
Former smoker | 11 (26.1) | 16 (38.1) | 13 (30.9) | |
Current smoker | 1 (2.4) | 2 (4.8) | 1 (2.4) | |
| Alcoholic drinks per week, mean ± sd | 4.0 ± 3.6 | 6.8 ± 10.7 | 4.4 ± 4.0 | 0.86 |
| Diabetes, n (%) | 4 (9.5) | 3 (7.1) | 5 (11.9) | 0.76 |
| Race, n (%) | 0.40 | |||
White | 31 (73.8) | 33 (78.5) | 32 (76.2) | |
African-American | 1 (2.4) | 1 (2.4) | 1 (2.4) | |
Hispanic | 5 (11.9) | 1 (2.4) | 3 (7.1) | |
Asian | 3 (7.1) | 1 (2.4) | 2 (4.8) | |
Other | 0 | 1 (2.4) | 3 (7.1) | |
Unknown
| 2 (4.8) | 5 (11.9) | 1 (2.4) |
SC, standard colonoscopy; CAC, cap-assisted colonoscopy; EAC, Endocuff-assisted colonoscopy; BMI, body mass index.
Chi-square was used to determine significance with respect to gender, race, smoking, and diabetes between groups. ANOVA was used to determine significance in age, BMI and the Kruskal-Wallis test was used to test for differences in alcohol consumption between groups. P .05 was considered significant.
Classified as “unknown” if patient declined to state or if unavailable from the medical record
Procedure characteristics.
| SC n = 42 | CAC n = 42 | EAC n = 42 |
| |
| Indication, n (%) | 0.29 | |||
Screening | 27 (64.3) | 32 (76.2) | 33 (78.5) | |
Surveillance | 15 (35.7) | 10 (23.8) | 9 (21.5) | |
| Boston Bowel Prep Score, mean ± sd | 8.9 ± 0.5 | 8.9 ± 0.5 | 8.9 ± 0.3 | 0.54 |
| Withdrawal time (minutes), mean ± sd | 12.9 ± 5.2 | 12.4 ± 5.6 | 13.0 ± 6.2 | 0.86 |
| Time to cecum (minutes), mean ± sd | 5.6 ± 3.8 | 6.0 ± 2.8 | 6.1 ± 3.3 | 0.77 |
SC, standard colonoscopy; CAC, cap-assisted colonoscopy; EAC, Endocuff-assisted colonoscopy.
Chi-square test used to determine differences in procedure indication and Boston bowel prep score between groups. A mixed effects ANOVA used to determine significance in withdrawal and cecum times between groups. P .05 was considered significant.
Procedure outcomes.
| SC n = 42 | CAC n = 42 | EAC n = 42 |
|
Q
| |
| Adenoma detection rate (ADR), n (%) | 22 (52.4) | 17 (40.5) | 23 (54.8) | 0.37 | .54 |
Proximal
| 19 (45.2) | 15 (35.7) | 21 (50.0) | 0.41 | .54 |
Distal
| 11 (26.2) | 5 (11.9) | 10 (23.8) | 0.22 | .51 |
| SSA detection rate, n (%) | 7 (16.7) | 6 (14.3) | 10 (23.8) | 0.50 | .54 |
| Adenoma mean size (mm), mean ± SD | 4.44 ± 0.4 | 5.20 ± 0.5 | 4.75 ± 0.4 | 0.54 | .54 |
| Mean adenoma per colonoscopy (APC) | 1.17 ± 1.3 | 0.76 ± 1.2 | 1.7 ± 2.3 | 0.03 | .21 |
| Mean adenoma per positive colonoscopy (APPC) | 2.08 ± 1.1 | 1.63 ± 1.4 | 2.6 ± 2.4 | 0.21 | .51 |
SC, standard colonoscopy; CAC, cap-assisted colonoscopy; EAC, Endocuff-assisted colonoscopy; SSA, sessile serrated adenoma
Included all adenomas proximal to the splenic flexure
Included all adenomas distal to the splenic flexure
Chi-square test was performed to determine significance for overall ADR, ADR by location and SSADR. A mixed-effects ANOVA was used to determine differences in adenoma size between treatment arms. An ANOVA was fit using all colonoscopies to test for differences in APC and APPC between the treatment arms. A P -value of .05 was considered significant.
Adjusted p-value controlling for the false discovery rate.